JNJ vs PTGX
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. PTGX: Protagonist Therapeutics is a biopharmaceutical company developing novel peptide-based therapies to treat chronic diseases through internal research and strategic collaborations.
Side-by-side fundamentals
| Metric | JNJ | PTGX | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $259.24 | $145.87 | |
| Market cap as of 2026-08-10 | $624.7B | $9.4B | |
| P/E as of 2026-08-10 | 29.70 | 113.85 | JNJ lower |
| PEG as of 2026-08-10 | 3.39 | 3.10 | PTGX lower |
| Net margin as of 2026-08-10 | +21.5% | +29.4% | PTGX higher |
| Gross margin as of 2026-08-10 | +68.0% | n/a | |
| Operating margin as of 2026-08-10 | +25.7% | +20.7% | JNJ higher |
| ROE as of 2026-08-10 | +25.7% | +12.0% | JNJ higher |
| ROA as of 2026-08-10 | +10.6% | +11.2% | PTGX higher |
| Debt / equity as of 2026-08-10 | 0.58 | 0.00 | PTGX lower |
| Revenue growth (YoY) as of 2026-08-10 | +8.1% | +34.8% | PTGX higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | n/a | |
| Dividend yield as of 2026-08-10 | +2.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-10 | 0.20 | 1.49 | |
| 1-year return as of 2026-08-07 close | +51.1% | +186.2% | PTGX higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.